The global diabetes therapeutics market in 2024 remains one of the most dynamic segments of the pharmaceutical industry. Growth is being powered by breakthrough GLP-1 receptor agonists, dual-action incretin therapies, and next-generation insulin formulations that deliver better glycemic control, weight benefits, and improved patient adherence.
Pharmaceutical leaders such as Novo Nordisk, Eli Lilly, Boehringer Ingelheim, AstraZeneca, and Sanofi continue to dominate sales, driven by blockbuster brands with strong clinical differentiation.
Below is a snapshot of the top 10 bestselling diabetes drugs worldwide in 2024, ranked by annual sales.
đź“Š Ranked by 2024 Sales
1. Ozempic – $16.7 Bn
Company: Novo Nordisk
Ozempic remains the world’s top-selling diabetes drug, fueled by its strong glucose-lowering efficacy and significant weight-loss benefits. Its success has also accelerated the broader GLP-1 market expansion.
2. Mounjaro – $11.5 Bn
Company: Eli Lilly
Mounjaro, a dual GIP/GLP-1 receptor agonist, has rapidly gained traction thanks to superior HbA1c reduction and weight outcomes, positioning it as a future market leader.
3. Jardiance – $9.5 Bn
Companies: Boehringer Ingelheim & Eli Lilly
A cornerstone SGLT2 inhibitor, Jardiance continues to benefit from strong evidence in cardiovascular and renal risk reduction.
4. Forxiga – $7.7 Bn
Company: AstraZeneca
Forxiga’s broad indications across diabetes, heart failure, and chronic kidney disease have made it a multi-billion-dollar franchise.
5. Trulicity – $5.3 Bn
Company: Eli Lilly
Despite rising competition, Trulicity remains widely prescribed due to its once-weekly dosing and long-standing physician familiarity.
6. Rybelsus – $3.2 Bn
Company: Novo Nordisk
As the first oral GLP-1 therapy, Rybelsus continues to attract patients seeking needle-free diabetes management.
7. Humalog – $2.3 Bn
Company: Eli Lilly
Humalog remains a key rapid-acting insulin, especially in intensive insulin therapy and hospital settings.
8. NovoRapid – $2.3 Bn
Company: Novo Nordisk
A widely used fast-acting insulin, NovoRapid continues to see stable demand across global markets.
9. Jentadueto / Trajenta – $1.8 Bn
Company: Boehringer Ingelheim
These DPP-4 inhibitor brands maintain relevance in patients requiring weight-neutral oral therapies.
10. Lantus – $1.7 Bn
Company: Sanofi
Once the world’s top insulin brand, Lantus still plays a major role in basal insulin therapy despite biosimilar competition.
🔍 Market Outlook
The 2024 rankings highlight a clear shift in diabetes care:
-
GLP-1 and dual incretin therapies are now the primary growth engines.
-
SGLT2 inhibitors continue expanding beyond diabetes into cardio-renal indications.
-
Insulin brands remain essential but face pricing pressure and biosimilar erosion.
Looking ahead, innovation in oral incretins, combination therapies, and obesity-diabetes crossover treatments is expected to further reshape the competitive landscape.